Coventry, United Kingdom
Medherant Limited, founded in 2015, is a United Kingdom-based clinical-stage company specializing in innovative drug delivery systems targeting pain and CNS diseases. Utilizing its proprietary TEPI Patch technology, developed from a unique adhesive created by Professor David Haddleton and the University of Warwick, Medherant delivers a pioneering approach to transdermal drug administration.
The TEPI Patch offers high drug loading capacity, allowing for thinner, more flexible patches that maintain strong adhesion, even in moist conditions, ensuring full drug delivery without skin residue post-application. This innovative technology enables customization of drug release profiles through the incorporation of permeation enhancers within the adhesive.
Collaboration plays a key role in Medherant's strategy, as the company conducts feasibility studies for external companies interested in transdermal delivery. The firm's recent investment milestone includes a £2.90M early-stage funding round led by Mercia as of April 2023, signifying robust investor confidence in its potential.
